{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T11:23:46Z","timestamp":1772277826043,"version":"3.50.1"},"reference-count":15,"publisher":"Georg Thieme Verlag KG","issue":"09","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Neuropsiquiatr"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent studies demonstrate a significant paradigm shift concerning migraine patients suffering from medication overuse (MO). Traditionally, doctors used to demand that patients who overused medications be withdrawn before beginning any preventive therapy; however, such a belief has recently been challenged by emerging evidence about the benefit of calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs), which have shown similar effectiveness in several clinical trials and real-world studies, regardless of whether a patient has previously stopped taking excessive medications. The data indicates that patients undergoing CGRP mAb therapy naturally decreased their acute medication consumption as migraine frequency diminished without requiring forced discontinuation. Furthermore, safety analyses have confirmed favorable tolerability profiles when CGRP mAbs are administered concurrently with various acute medications. This new evidence-based approach offers several clinical advantages, including enhanced treatment adherence and reduced risk of withdrawal complications. These findings support transitioning from mandatory detoxification protocols toward more individualized treatment strategies, representing a significant advancement in clinical migraine management.<\/jats:p>","DOI":"10.1055\/s-0045-1809658","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T22:49:03Z","timestamp":1753742943000},"page":"001-003","source":"Crossref","is-referenced-by-count":2,"title":["Calcitonin gene-related peptide monoclonal antibodies and medication overuse headache: is stopping excessive pain medication still necessary?"],"prefix":"10.1055","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1070-5552","authenticated-orcid":false,"given":"Jo\u00e3o Jos\u00e9 Freitas de","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina Unichristus, Fortaleza CE, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00409-9","article-title":"Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions","volume":"21","author":"L Al-Hassany","year":"2022","journal-title":"Lancet Neurol"},{"issue":"07","key":"ref2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1177\/03331024211067791","article-title":"Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache","volume":"42","author":"U Pensato","year":"2022","journal-title":"Cephalalgia"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1129439","DOI":"10.3389\/fneur.2023.1129439","article-title":"Monoclonal antibodies for chronic migraine and medication overuse headache: A real-world study","volume":"14","author":"A V Krymchantowski","year":"2023","journal-title":"Front Neurol"},{"issue":"01","key":"ref4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s10194-024-01813-3","article-title":"Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysis","volume":"25","author":"A Scheffler","year":"2024","journal-title":"J Headache Pain"},{"issue":"01","key":"ref5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-021-01328-1","article-title":"Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6\u2009months","volume":"22","author":"E Caronna","year":"2021","journal-title":"J Headache Pain"},{"issue":"23","key":"ref6","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.2169\/internalmedicine.1471-22","article-title":"Early Effect of Calcitonin Gene-related Peptide Monoclonal Antibodies in Migraine with Medication Overuse: A Single-center Retrospective Study","volume":"62","author":"Y Ito","year":"2023","journal-title":"Intern Med"},{"issue":"19","key":"ref7","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.3390\/jcm10194586","article-title":"CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab","volume":"10","author":"C De Luca","year":"2021","journal-title":"J Clin Med"},{"issue":"22","key":"ref8","doi-asserted-by":"publisher","first-page":"e40190","DOI":"10.1016\/j.heliyon.2024.e40190","article-title":"Real-world clinical results of CGRP monoclonal antibody treatment for medication overuse headache of migraine without abrupt drug discontinuation and no hospitalization","volume":"10","author":"T Tanei","year":"2024","journal-title":"Heliyon"},{"issue":"06","key":"ref9","doi-asserted-by":"publisher","first-page":"e2799","DOI":"10.1002\/brb3.2799","article-title":"Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real-world clinical evidence in a severely impaired patient population","volume":"13","author":"S Guerzoni","year":"2023","journal-title":"Brain Behav"},{"issue":"04","key":"ref10","doi-asserted-by":"publisher","first-page":"3331024231160519","DOI":"10.1177\/03331024231160519","article-title":"Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study","volume":"43","author":"L F Iannone","year":"2023","journal-title":"Cephalalgia"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"846717","DOI":"10.3389\/fneur.2022.846717","article-title":"Acute Medication Use in Patients With Migraine Treated With Monoclonal Antibodies Acting on the CGRP Pathway: Results From a Multicenter Study and Proposal of a New Index","volume":"13","author":"L Sette","year":"2022","journal-title":"Front Neurol"},{"issue":"03","key":"ref12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/WCO.0000000000001061","article-title":"Therapies targeting CGRP signaling for medication overuse headache","volume":"35","author":"I A Koumprentziotis","year":"2022","journal-title":"Curr Opin Neurol"},{"issue":"07","key":"ref13","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/ene.14268","article-title":"European Academy of Neurology guideline on the management of medication-overuse headache","volume":"27","author":"H C Diener","year":"2020","journal-title":"Eur J Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10072-020-04690-1","article-title":"Effectiveness of erenumab in chronic migraine patients with associated medication overuse headache: a prospective observational study","volume":"41","author":"M Curone","year":"2020","journal-title":"Neurol Sci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10072-020-04670-5","article-title":"Erenumab efficacy in chronic migraine and medication overuse: a real-life multicentric Italian observational study","volume":"41","author":"F S Di Cola","year":"2020","journal-title":"Neurol Sci"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0045-1809658.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T22:49:04Z","timestamp":1753742944000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0045-1809658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":15,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2025,6,21]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["s00451809658"],"URL":"https:\/\/doi.org\/10.1055\/s-0045-1809658","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0004-282X","1678-4227"],"issn-type":[{"value":"0004-282X","type":"print"},{"value":"1678-4227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]}}}